Copyright Reports & Markets. All rights reserved.

Covid-19 Impact on Induced Pluripotent Stem Cells Market, Global Research Reports 2020-2021

Request for Sample of this report
Buy now
  • 1.1 Research Scope
  • 1.2 Market Segmentation
  • 1.3 Research Objectives
  • 1.4 Research Methodology
    • 1.4.1 Research Process
    • 1.4.2 Data Triangulation
    • 1.4.3 Research Approach
    • 1.4.4 Base Year
  • 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
    • 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
    • 1.5.2 Covid-19 Impact: Commodity Prices Indices
    • 1.5.3 Covid-19 Impact: Global Major Government Policy
  • 1.6 The Covid-19 Impact on Induced Pluripotent Stem Cells Industry
  • 1.7 COVID-19 Impact: Induced Pluripotent Stem Cells Market Trends

    • 2 Global Induced Pluripotent Stem Cells Quarterly Market Size Analysis

    • 2.1 Induced Pluripotent Stem Cells Business Impact Assessment - COVID-19
      • 2.1.1 Global Induced Pluripotent Stem Cells Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
    • 2.2 Global Induced Pluripotent Stem Cells Quarterly Market Size 2020-2021
    • 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
      • 2.3.1 Drivers
      • 2.3.2 Restraints
      • 2.3.3 Opportunities
      • 2.3.4 Challenges

    3 Quarterly Competitive Assessment, 2020

    • 3.1 By Players, Global Induced Pluripotent Stem Cells Quarterly Market Size, 2019 VS 2020
    • 3.2 By Players, Induced Pluripotent Stem Cells Headquarters and Area Served
    • 3.3 Date of Key Players Enter into Induced Pluripotent Stem Cells Market
    • 3.4 Key Players Induced Pluripotent Stem Cells Product Offered
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Impact of Covid-19 on Induced Pluripotent Stem Cells Segments, By Type

    • 4.1 Introduction
      • 1.4.1 Hepatocytes
      • 1.4.2 Fibroblasts
      • 1.4.3 Keratinocytes
      • 1.4.4 Amniotic Cells
      • 1.4.5 Others
    • 4.2 By Type, Global Induced Pluripotent Stem Cells Market Size, 2019-2021

    5 Impact of Covid-19 on Induced Pluripotent Stem Cells Segments, By Application

    • 5.1 Overview
      • 5.5.1 Academic Research
      • 5.5.2 Drug Development And Discovery
      • 5.5.3 Toxicity Screening
      • 5.5.4 Regenerative Medicine
    • 5.2 By Application, Global Induced Pluripotent Stem Cells Market Size, 2019-2021
      • 5.2.1 By Application, Global Induced Pluripotent Stem Cells Market Size by Application, 2019-2021

    6 Geographic Analysis

    • 6.1 Introduction
    • 6.2 North America
      • 6.2.1 Macroeconomic Indicators of US
      • 6.2.2 US
      • 6.2.3 Canada
    • 6.3 Europe
      • 6.3.1 Macroeconomic Indicators of Europe
      • 6.3.2 Germany
      • 6.3.3 France
      • 6.3.4 UK
      • 6.3.5 Italy
    • 6.4 Asia-Pacific
      • 6.4.1 Macroeconomic Indicators of Asia-Pacific
      • 6.4.2 China
      • 6.4.3 Japan
      • 6.4.4 South Korea
      • 6.4.5 India
      • 6.4.6 ASEAN
    • 6.5 Rest of World
      • 6.5.1 Latin America
      • 6.5.2 Middle East and Africa

    7 Company Profiles

    • 7.1 Fujifilm Holding Corporation
      • 7.1.1 Fujifilm Holding Corporation Business Overview
      • 7.1.2 Fujifilm Holding Corporation Induced Pluripotent Stem Cells Quarterly Revenue, 2020
      • 7.1.3 Fujifilm Holding Corporation Induced Pluripotent Stem Cells Product Introduction
      • 7.1.4 Fujifilm Holding Corporation Response to COVID-19 and Related Developments
    • 7.2 Astellas Pharma
      • 7.2.1 Astellas Pharma Business Overview
      • 7.2.2 Astellas Pharma Induced Pluripotent Stem Cells Quarterly Revenue, 2020
      • 7.2.3 Astellas Pharma Induced Pluripotent Stem Cells Product Introduction
      • 7.2.4 Astellas Pharma Response to COVID-19 and Related Developments
    • 7.3 Fate Therapeutics
      • 7.3.1 Fate Therapeutics Business Overview
      • 7.3.2 Fate Therapeutics Induced Pluripotent Stem Cells Quarterly Revenue, 2020
      • 7.3.3 Fate Therapeutics Induced Pluripotent Stem Cells Product Introduction
      • 7.3.4 Fate Therapeutics Response to COVID-19 and Related Developments
    • 7.4 Bristol-Myers Squibb Company
      • 7.4.1 Bristol-Myers Squibb Company Business Overview
      • 7.4.2 Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Quarterly Revenue, 2020
      • 7.4.3 Bristol-Myers Squibb Company Induced Pluripotent Stem Cells Product Introduction
      • 7.4.4 Bristol-Myers Squibb Company Response to COVID-19 and Related Developments
    • 7.5 ViaCyte
      • 7.5.1 ViaCyte Business Overview
      • 7.5.2 ViaCyte Induced Pluripotent Stem Cells Quarterly Revenue, 2020
      • 7.5.3 ViaCyte Induced Pluripotent Stem Cells Product Introduction
      • 7.5.4 ViaCyte Response to COVID-19 and Related Developments
    • 7.6 Celgene Corporation
      • 7.6.1 Celgene Corporation Business Overview
      • 7.6.2 Celgene Corporation Induced Pluripotent Stem Cells Quarterly Revenue, 2020
      • 7.6.3 Celgene Corporation Induced Pluripotent Stem Cells Product Introduction
      • 7.6.4 Celgene Corporation Response to COVID-19 and Related Developments
    • 7.7 Aastrom Biosciences
      • 7.7.1 Aastrom Biosciences Business Overview
      • 7.7.2 Aastrom Biosciences Induced Pluripotent Stem Cells Quarterly Revenue, 2020
      • 7.7.3 Aastrom Biosciences Induced Pluripotent Stem Cells Product Introduction
      • 7.7.4 Aastrom Biosciences Response to COVID-19 and Related Developments
    • 7.8 Acelity Holdings
      • 7.8.1 Acelity Holdings Business Overview
      • 7.8.2 Acelity Holdings Induced Pluripotent Stem Cells Quarterly Revenue, 2020
      • 7.8.3 Acelity Holdings Induced Pluripotent Stem Cells Product Introduction
      • 7.8.4 Acelity Holdings Response to COVID-19 and Related Developments
    • 7.9 StemCells
      • 7.9.1 StemCells Business Overview
      • 7.9.2 StemCells Induced Pluripotent Stem Cells Quarterly Revenue, 2020
      • 7.9.3 StemCells Induced Pluripotent Stem Cells Product Introduction
      • 7.9.4 StemCells Response to COVID-19 and Related Developments
    • 7.10 Japan Tissue Engineering
      • 7.10.1 Japan Tissue Engineering Business Overview
      • 7.10.2 Japan Tissue Engineering Induced Pluripotent Stem Cells Quarterly Revenue, 2020
      • 7.10.3 Japan Tissue Engineering Induced Pluripotent Stem Cells Product Introduction
      • 7.10.4 Japan Tissue Engineering Response to COVID-19 and Related Developments
    • 7.11 Organogenesis
      • 7.11.1 Organogenesis Business Overview
      • 7.11.2 Organogenesis Induced Pluripotent Stem Cells Quarterly Revenue, 2020
      • 7.11.3 Organogenesis Induced Pluripotent Stem Cells Product Introduction
      • 7.11.4 Organogenesis Response to COVID-19 and Related Developments

    8 Key Findings

      9 Appendix

      • 9.1 About US

      This report covers market size and forecasts of Induced Pluripotent Stem Cells, including the following market information:
      Global Induced Pluripotent Stem Cells Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Induced Pluripotent Stem Cells Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Induced Pluripotent Stem Cells Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)
      Global Induced Pluripotent Stem Cells Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

      Key market players
      Major competitors identified in this market include Fujifilm Holding Corporation, Astellas Pharma, Fate Therapeutics, Bristol-Myers Squibb Company, ViaCyte, Celgene Corporation, Aastrom Biosciences, Acelity Holdings, StemCells, Japan Tissue Engineering, Organogenesis, etc.

      Based on the Region:
      Asia-Pacific (China, Japan, South Korea, India and ASEAN)
      North America (US and Canada)
      Europe (Germany, France, UK and Italy)
      Rest of World (Latin America, Middle East & Africa)

      Based on the Type:
      Hepatocytes
      Fibroblasts
      Keratinocytes
      Amniotic Cells
      Others

      Based on the Application:
      Academic Research
      Drug Development And Discovery
      Toxicity Screening
      Regenerative Medicine

      Buy now